UBS AM
DYN icon

UBS AM’s Dyne Therapeutics DYN Stock Holding History

UBS AM’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.34M Buy
239,285
+24,794
+12% +$428K ﹤0.01% 1634
2025
Q4 		$4.2M Sell
214,491
-14,939
-7% -$283K ﹤0.01% 1554
2025
Q3 		$2.9M Sell
229,430
-64,214
-22% -$732K ﹤0.01% 1606
2025
Q2 		$2.8M Buy
293,644
+135,853
+86% +$1.5M ﹤0.01% 1992
2025
Q1 		$1.65M Buy
157,791
+14,428
+10% +$206K ﹤0.01% 2083
2024
Q4 		$3.38M Buy
143,363
+9,029
+7% +$267K ﹤0.01% 1793
2024
Q3 		$4.83M Buy
134,334
+6,784
+5% +$270K ﹤0.01% 1590
2024
Q2 		$4.5M Buy
127,550
+96,269
+308% +$2.8M ﹤0.01% 1548
2024
Q1 		$888K Buy
31,281
+5,892
+23% +$133K ﹤0.01% 2072
2023
Q4 		$338K Buy
25,389
+13,167
+108% +$129K ﹤0.01% 2400
2023
Q3 		$110K Hold
12,222
– – ﹤0.01% 2559
2023
Q2 		$141K Hold
12,222
– – ﹤0.01% 2610
2023
Q1 		$141K Hold
12,222
– – ﹤0.01% 2610
2022
Q4 		$142K Hold
12,222
– – ﹤0.01% 2478
2022
Q3 		$155K Hold
12,222
– – ﹤0.01% 2644
2022
Q2 		$84K Hold
12,222
– – ﹤0.01% 2658
2022
Q1 		$118K Hold
12,222
– – ﹤0.01% 2728
2021
Q4 		$145K Hold
12,222
– – ﹤0.01% 2794
2021
Q3 		$198K Buy
+12,222
New +$217K ﹤0.01% 2694

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

UBS AM's DYN Position: Q1 2026 in Review

UBS AM increased its Dyne Therapeutics (DYN) stake by 12% in Q1 2026, buying an estimated $428K and bringing the position to 239,285 shares worth $4.34M. The position accounts for ﹤0.01% of the portfolio, ranked #1634.

UBS AM first reported a position in DYN in Q3 2021 and has held it in 19 quarters since. The position peaked at $4.83M in Q3 2024. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

  • UBS AM held 239,285 shares of Dyne Therapeutics worth $4.34M as of Q1 2026.
  • UBS AM bought 24,794 Dyne Therapeutics shares in Q1 2026, an estimated $428K.
  • Dyne Therapeutics made up ﹤0.01% of UBS AM's portfolio in Q1 2026, its #1634 holding.
  • UBS AM first reported a position in Dyne Therapeutics in Q3 2021 and has held it in 19 quarters since.
  • UBS AM's Dyne Therapeutics position peaked at $4.83M in Q3 2024.
  • 227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on UBS AM's 13F filing for Q1 2026, filed 13 May 2026.